High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome.
We treated 5 patients with polyneuropathy, organomegaly, endocrinopathy, monoclonal gammopathy, and skin changes (POEMS) syndrome and multifocal bone lesions or diffuse bone marrow plasmacytic infiltration with high-dose therapy (HDT) and autologous blood stem cell transplantation. In all cases, the treatment produced remission of plasma cell proliferation associated with marked improvement in the patients' performance status, neurologic symptoms, and other manifestations of the syndrome. HDT with stem cell support should be investigated further as a therapeutic option in patients with POEMS syndrome and disseminated plasma cell dyscrasia.
Jaccard
Arnaud
A
Hematology Unit, Centre Hospitalier Universitaire, Limoges, France.
Royer
Bruno
B
Bordessoule
Dominique
D
Brouet
Jean-Claude
JC
Fermand
Jean-Paul
JP
D000328:Adult; D018906:Antineoplastic Agents, Alkylating / Q000008:administration & dosage*; D002999:Clone Cells / Q000276:immunology / Q000473:pathology; D003131:Combined Modality Therapy; D004305:Dose-Response Relationship, Drug; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007136:Immunoglobulins / Q000097:blood / Q000652:urine; D008297:Male; D008558:Melphalan / Q000008:administration & dosage; D008875:Middle Aged; D009422:Nervous System Diseases / Q000209:etiology; D016878:POEMS Syndrome / Q000150:complications / Q000473:pathology / Q000628:therapy*; D010950:Plasma Cells / Q000276:immunology / Q000473:pathology; D012074:Remission Induction; D014182:Transplantation, Autologous; D016896:Treatment Outcome
D018906:Antineoplastic Agents, Alkylating; D007136:Immunoglobulins; D008558:Melphalan